%0 Journal Article
%T Trade-offs between drug toxicity and benefit in the multi-antibiotic resistance system underlie optimal growth of E. coli
%A Kevin B Wood
%A Philippe Cluzel
%J BMC Systems Biology
%D 2012
%I BioMed Central
%R 10.1186/1752-0509-6-48
%X Here, we use the well-studied multiple antibiotic resistance (MAR) system in E. coli to experimentally characterize the trade-off between drug toxicity (¡°cost¡±) and drug-induced resistance (¡°benefit¡±) mediated by efflux pumps. Specifically, we show that the combined effects of a MAR-inducing drug and an antibiotic are governed by a superposition of cost and benefit functions that govern these trade-offs. We find that this superposition holds for all drug concentrations, and it therefore allows us to describe the full dose¨Cresponse diagram for a drug pair using simpler cost and benefit functions. Moreover, this framework predicts the existence of optimal growth at a non-trivial concentration of inducer. We demonstrate that optimal growth does not coincide with maximum induction of the mar promoter, but instead results from the interplay between drug toxicity and mar induction. Finally, we derived and experimentally validated a general phase diagram highlighting the role of these opposing effects in shaping the interaction between two drugs.Our analysis provides a quantitative description of the MAR system and highlights the trade-off between inducible resistance and the toxicity of the inducing agent in a multi-component environment. The results provide a predictive framework for the combined effects of drug toxicity and induction of the MAR system that are usually masked by bulk measurements of bacterial growth. The framework may also be useful for identifying optimal growth conditions in more general systems where combinations of environmental cues contribute to both transient resistance and toxicity.The resistance of bacteria to antibiotics has prompted intense scientific research in the last several decades because it directly underlies the clinical treatment of infections [1]. While a large number of studies have focused on mutation-driven resistance, recent attention has also shifted to transient, or ¡°inducible¡±, drug resistance taking place on much shorter tim
%U http://www.biomedcentral.com/1752-0509/6/48